Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Estimating population-based incidence of community-acquired pneumonia and acute otitis media in children and adults in Ontario and British Columbia using health administrative data, 2005-2018: a Canadian Immunisation Research Network (CIRN) study.

Authors:
Sharifa Nasreen Jun Wang Manish Sadarangani Jeffrey C Kwong Caroline Quach Natasha S Crowcroft Sarah E Wilson Allison McGeer Shaun K Morris James D Kellner Beate Sander Julianne V Kus Linda Hoang Fawziah Marra Shaza A Fadel

BMJ Open Respir Res 2022 06;9(1)

Centre for Vaccine Preventable Diseases, University of Toronto, Toronto, Ontario, Canada

Background: There is a paucity of data on the burden of the full spectrum of community-acquired pneumonia (CAP) and acute otitis media (AOM) from outpatient and inpatient settings across the age spectrum.

Methods: We conducted a population-based retrospective study in Ontario and British Columbia (BC), Canada, to estimate the incidence rate of CAP and AOM in children and adults over a 14-year period using health administrative databases. CAP and AOM cases were identified from outpatient physician consultation and hospitalisation data in both provinces, and from emergency department visit data in Ontario.

Results: During 2005-2018, Ontario had 3 607 124 CAP, 172 290 bacterial CAP, 7814 pneumococcal pneumonia, and 8 026 971 AOM cases. The incidence rate of CAP declined from 3077/100 000 in 2005 to 2604/100 000 in 2010 before increasing to 2843/100 000 in 2018; bacterial CAP incidence rate also declined from 178/100 000 in 2005 to 112/100 000 in 2010 before increasing to 149/100 000 in 2018. The incidence rate of AOM decreased from 4192/100 000 in 2005 to 3178/100 000 in 2018. BC had 970 455 CAP, 317 913 bacterial CAP, 35 287 pneumococcal pneumonia and 2 022 871 AOM cases. The incidence rate of CAP in BC decreased from 2214/100 000 in 2005 to 1964/100 000 in 2010 before increasing to 2176/100 000 in 2018; bacterial CAP incidence rate increased from 442/100 000 in 2005 to 981/100 000 in 2018. The incidence rate of AOM decreased from 3684/100 000 in 2005 to 2398/100 000 in 2018. The incidence rate of bacterial CAP increased with age in older adults (≥65 years) with the highest burden in the oldest cohort aged ≥85 years both before and after 13-valent pneumococcal conjugate vaccine (PCV13) programme in both provinces. Hospitalised pneumococcal pneumonia decreased slightly but non-hospitalised pneumococcal pneumonia increased in BC during PCV13 period. No consistent direct benefit of PCV13 on CAP was observed in the paediatric population.

Conclusions: There is a substantial burden of CAP and AOM in Ontario and BC. Indirect benefits from childhood PCV vaccination and polysaccharide vaccination of older adults have not substantially decreased the burden of pneumococcal pneumonia in older adults.

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjresp-2022-001218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240885PMC
June 2022

Publication Analysis

Top Keywords

incidence rate
32
000 2018
24
000 2005
24
pneumococcal pneumonia
20
bacterial cap
20
000
15
cap
14
2018 incidence
12
rate cap
12
cap aom
12
2010 increasing
12
000 2010
12
older adults
12
aom cases
12
incidence
9
rate aom
8
aom decreased
8
rate
8
cases incidence
8
health administrative
8

Keyword Occurance

Similar Publications

Klinefelter syndrome: going beyond the diagnosis.

Authors:
Gary Butler Umasuthan Srirangalingam Jennie Faithfull Philippa Sangster Senthil Senniappan Rod Mitchell

Arch Dis Child 2022 Aug 10. Epub 2022 Aug 10.

MRC Centre for Reproductive Health, University of Edinburgh Division of Reproductive and Developmental Sciences, Edinburgh, UK.

Although Klinefelter syndrome (KS) is common, it is rarely recognised in childhood, sometimes being identified with speech or developmental delay or incidental antenatal diagnosis. The only regular feature is testicular dysfunction. Postnatal gonadotropin surge (mini-puberty) may be lower, but treatment with testosterone needs prospective studies. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Genomic analyses of Pamir argali, Tibetan sheep, and their hybrids provide insights into chromosome evolution, phenotypic variation, and germplasm innovation.

Authors:
Xin Li San-Gang He Wen-Rong Li Ling-Yun Luo Ze Yan Dong-Xin Mo Xing Wan Feng-Hua Lv Ji Yang Ya-Xi Xu Juan Deng Qiang-Hui Zhu Xing-Long Xie Song-Song Xu Chen-Xi Liu Xin-Rong Peng Bin Han Zhong-Hui Li Lei Chen Jian-Lin Han Xue-Zhi Ding Renqing Dingkao Yue-Feng Chu Jin-Yan Wu Li-Min Wang Ping Zhou Ming-Jun Liu Menghua Li

Genome Res 2022 Aug 10. Epub 2022 Aug 10.

China Agricultural University;

Understanding the genetic mechanisms of phenotypic variation in hybrids between domestic animals and their wild relatives may aid germplasm innovation. Here, we report the high-quality genome assemblies and high-throughput sequencing of 425 ovine animals, including the Pamir argali (O. ammon polii, 2n = 56), Tibetan sheep (O. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

Chlamydia Vaccination: Parent Opinions and Implications for Future Promotion Programs.

Authors:
Alison Footman Nita Kanney Linda M Niccolai Gregory D Zimet Edgar Turner Overton Susan L Davies Barbara Van Der Pol

Sex Transm Dis 2022 Aug 11. Epub 2022 Aug 11.

Tulane University, School of Social Work, New Orleans, LA, USA.

Introduction: Chlamydia vaccines are currently under development and have the potential to lower incidence of infection and disease, which are highest among adolescents and young adults. Ideally, a chlamydia vaccine would be administered to adolescents before sexual debut, a time when parents are the primary vaccine decision-makers. This study explores parent opinions about an adolescent chlamydia vaccine to understand barriers and facilitators to uptake. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

The Korea National Patient Safety Incidents Inquiry Survey: Characteristics of Adverse Events Identified Through Medical Records Review in Regional Public Hospitals.

Authors:
Min Ji Kim Hee Jung Seo Hong Mo Koo Minsu Ock Jee-In Hwang Sang-Il Lee

J Patient Saf 2022 Aug;18(5):382-388

Department of Preventive Medicine, University of Ulsan College of Medicine.

Objectives: In 2019, the Korean National Patient Safety Incidents Inquiry was conducted in the Republic of Korea to identify the national-level incidence of adverse events. This study determined the incidence and detailed the characteristics of adverse events at 15 regional public hospitals in the Republic of Korea.

Methods: Medical records data of 500 randomly selected patients (discharged in 2016) were extracted from each of the 15 studied hospitals and reviewed in 3 stages. Read More

View Article and Full-Text PDF
August 2022
Similar Publications

A Phase I/II Study of Intrathecal Trastuzumab in HER-2 Positive Cancer with Leptomeningeal Metastases: Safety, Efficacy, and Cerebrospinal Fluid Pharmacokinetics.

Authors:
Priya U Kumthekar Michael J Avram Andrew B Lassman Nancy U Lin Eudocia Lee Sean A Grimm Margaret Schwartz Kirsten L Bell Burdett Rimas V Lukas Karan Dixit Isabella Perron Hui Zhang William J Gradishar Elena I Pentsova Suriya Jeyapalan Morris D Groves Michelle Melisko Jeffrey J Raizer

Neuro Oncol 2022 Aug 10. Epub 2022 Aug 10.

Department of Neurology at The Feinberg School of Medicine at Northwestern University and The Malnati Brain Tumor Institute at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Chicago, IL.

Background: Patients with human epidermal growth factor receptor 2-positive (HER2-positive) cancers have a high incidence of central nervous system (CNS) spread, but unfortunately systemic trastuzumab which targets the HER2 receptor has little CNS penetration. The purpose of this study was to determine the maximum tolerated dose of intrathecal trastuzumab and its efficacy in patients with HER2-positive LMD.

Methods: This multicenter study enrolled 34 LMD patients in a combined Phase I/II study in treating patients with intrathecal trastuzumab. Read More

View Article and Full-Text PDF
August 2022
Similar Publications
}
© 2022 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap